Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 19/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 18/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 12/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6870814 | 0.83 | RXRA (0.32) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6158663 | 0.83 | RXRA (0.32) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4612808 | 0.82 | PTGS2 (0.47) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6755892 | 0.82 | RXRA (0.31) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6756526 | 0.81 | PTGS2 (0.34) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6758648 | 0.81 | PTGS2 (0.33) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4613161 | 0.80 | PTGS2 (0.50) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6761070 | 0.80 | RXRA (0.30) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4612261 | 0.78 | PTGS2 (0.48) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6153090 | 0.77 | PTGS2 (0.48) | PTGS2PTGS1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720423-B2 | SKIN RELATED DISEASES; PROMOTE THE EXPRESSION OF OR BIND TO RECEPTORS BELONGING TO THE STEROID OR THYROID RECEPTOR SUPERFAMILY. | ALLERGAN, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030216570-A1 | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | ALLERGAN, INC. | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216570-A1 | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | RXRB, RXRA, RXRG | PTGS2 1241/4885PTGS1 973/4885ALOX5 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.